Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.

Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. 
Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. 

However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.

This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France.
The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).

Mediolanum Farmaceutici S.p.A.

Mirae Capital

Newton Biocapital

CMS Medical Venture Investment

Karista

Mirae Asset

GO CAPITAL

A&B (HK)

Anaxago

Acticor Biotech

[#GlenzoPaper]

🌟 Exciting News! ACTIMIS Clinical Study Results have been officially published in The Lancet Neurology Journal 🧠🌐 

📰 Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a phase 1b/2a randomized, placebo-controlled, trial 

🔎 This article highlights key outcomes from the ACTIMIS study : 

✅ Achievement of ACTIMIS primary endpoint, confirming the safety of glenzocimab in acute ischemic stroke patients

📉 Reduction in the rate and severity of intracranial hemorrhages and of mortality in glenzocimab-treated patients

🔗Access the full paper on The Lancet website : https://lnkd.in/etYUfpMq

#ACTIMIS #MedicalResearch #StrokeTreatment #HealthcareInnovation

[#GlenzoPaper]

🎙️ Gilles Avenard, CEO d'Acticor Biotech, revient sur la parution des résultats d'ACTIMIS dans The Lancet lors d'un entretien avec Nathalie Brafman dans Le Monde 🌍 

🔗 Lien vers l'article : https://lnkd.in/e-Pu4jnu

#interview #ACTIMIS #LeMonde

[#GlenzoPaper]

"AVC - l'anticorps d'une biotech française qui pourrait réduire de moitié le risque de décès" 🚑 

✍ Publié dans Le Figaro, cet article revient sur la publication des résultats de l'étude ACTIMIS dans The Lancet Neurogoly avec le témoignage du Pr. Charlotte Cordonnier - chef du service de neurologie vasculaire au CHU de Lille et celui du Pr. Mikael Mazighi - chef du service de neurologie à l'hôpital Lariboisère 🗣 📰

Lien de l'article : https://lnkd.in/ewMunHan 🌐 

#ACTIMIS #interview #glenzocimab

[#GlenzoPaper]

Aujourd'hui, le Pr. Mikael Mazighi, chef de la neurologie à l'hôpital Lariboisière et coordinateur principal de l'étude ACTIMIS, était invité dans le Journal de 8h animé par Florence Paracuellos sur France Inter 🎙️

Il a partagé plus en détail les résultats de l'étude récemment publiés dans The Lancet ! 📊

Si vous avez manqué l'interview, vous pouvez trouver le podcast du journal ici (01:29 - 03:10) :  https://lnkd.in/eWVhdYwJ
Et pour plus d'infos, jetez un œil à l'article : https://lnkd.in/e9m5zqMs 📰

#ACTIMIS #interview #glenzocimab 

Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.

COM:ACTICOR-BIOTECH

Acticor Biotech

Last Close

0.30

25/11 08:00

Market Cap

8.67M

Beta: -

Volume Today

50

Avg: -

Filings Not Available